Coburn Sally B, Stanczyk Frank Z, Falk Roni T, McGlynn Katherine A, Brinton Louise A, Sampson Joshua, Bradwin Gary, Xu Xia, Trabert Britton
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA.
Departments of Obstetrics and Gynecology, and Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Cancer Causes Control. 2019 Jan;30(1):75-86. doi: 10.1007/s10552-018-1105-1. Epub 2018 Dec 1.
The comparability between serum, plasma, and urinary measurements of estrogen metabolites via liquid chromatography-tandem mass spectrometry (LC-MS/MS) has not been largely explored, and it is unclear if urinary LC-MS/MS measurements are suitable surrogates of circulating levels.
Serum, plasma (EDTA and heparin), and urinary estrogen/estrogen metabolite levels were measured via LC-MS/MS in paired samples from 64 healthy volunteers (18 men, 20 premenopausal women, 26 postmenopausal women). Geometric means and Spearman correlation coefficients were used to compare individual and combined pathway levels of estrogens/estrogen metabolites across biologic matrices by sex/menopausal status.
Measured concentrations of estrogens/estrogen metabolites across blood matrices were almost identical (percent differences < 4.8%). Parent estrogen concentrations measured in serum and urine were moderately correlated in postmenopausal women (estrone: r = 0.69, estradiol: r = 0.69). Correlations were similar comparing unconjugated serum estradiol to urinary estrone (r = 0.76) and urinary estradiol (r = 0.65) in postmenopausal women but were moderate to low in premenopausal women (r = 0.60, 0.40, respectively)/men (r = 0.33, 0.53, respectively). Comparing metabolite ratios, proportionally higher concentrations of 16-pathway metabolites were measured in urine versus serum across sex/menopausal status groups (e.g., postmenopausal women: 50.3% 16-pathway metabolites/total in urine versus 35.3% in serum).
There is strong agreement between estrogen/estrogen metabolites measurements in serum, heparin plasma, and EDTA plasma. Individual estrogen metabolite concentrations were moderately correlated between urine and serum, but were not well correlated when evaluating pathway- or relative estrogen concentrations. Differences between serum and urine are likely explained by differences in metabolism and/or excretion.
液相色谱 - 串联质谱法(LC-MS/MS)测定血清、血浆和尿液中雌激素代谢物的可比性尚未得到充分研究,目前尚不清楚尿液LC-MS/MS测量是否适合作为循环水平的替代指标。
通过LC-MS/MS对64名健康志愿者(18名男性、20名绝经前女性、26名绝经后女性)的配对样本进行血清、血浆(乙二胺四乙酸和肝素抗凝)和尿液中雌激素/雌激素代谢物水平的测定。采用几何均数和Spearman相关系数,按性别/绝经状态比较生物基质中雌激素/雌激素代谢物的个体及合并途径水平。
血液基质中雌激素/雌激素代谢物的测量浓度几乎相同(百分比差异<4.8%)。绝经后女性血清和尿液中测得的母体雌激素浓度呈中度相关(雌酮:r = 0.69,雌二醇:r = 0.69)。绝经后女性中,未结合血清雌二醇与尿液雌酮(r = 0.76)和尿液雌二醇(r = 0.65)的相关性相似,但绝经前女性(分别为r = 0.60、0.40)/男性(分别为r = 0.33、0.53)的相关性为中度至低度。比较代谢物比率,在各性别/绝经状态组中,尿液中16-途径代谢物的浓度相对血清而言比例更高(例如,绝经后女性:尿液中16-途径代谢物占总量的50.3%,血清中为35.3%)。
血清、肝素抗凝血浆和乙二胺四乙酸抗凝血浆中雌激素/雌激素代谢物的测量结果高度一致。尿液和血清中个体雌激素代谢物浓度呈中度相关,但在评估途径或相对雌激素浓度时相关性不佳。血清和尿液之间的差异可能由代谢和/或排泄差异所解释。